Testing rFVIIa for bleeding stroke within 2 hours
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a drug called Recombinant Factor VIIa (rFVIIa) can safely help stop bleeding in the brain during a hemorrhagic stroke. The goal is to give the drug as quickly as possible, within 2 hours of stroke onset, to see if it improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of stroke called spontaneous intracerebral hemorrhage (bleeding in the brain) not caused by injury or other known conditions.
- You can get the study drug within 2 hours of your stroke starting (or 1.5 hours if a certain sign on CT is absent).
- You have not taken blood thinners (like warfarin or newer oral anticoagulants) within the last week.
- You have no major disability before the stroke, no recent blood clots or heart problems, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether a blood thinner (apixaban) can help prevent another stroke and support recovery after you’ve had a brain bleed. You would be assigned to a treatment group, and the study checks safety and whether strokes can be reduced without causing dangerous bleeding.
This study tests a drug called Cerebrolysin, which may help protect the brain after a bleeding stroke. It is given within 6 hours of the stroke, and researchers will check if it is safe and helps improve recovery.
This trial looks at whether starting brain surgery within 8 hours after a type of stroke called intracerebral hemorrhage (bleeding in the brain) can improve outcomes. It’s for adults with a certain amount and location of bleeding and without common causes like an aneurysm or malformation.
This study tests whether the drug tranexamic acid can help stop bleeding in the brain when given early. It is for people with a spontaneous brain bleed who are awake and can be treated within 6 hours.
This study collects blood samples from people with and without bleeding risk to test a clot-dissolving drug (tPA) outside the body. It aims to improve minimally invasive surgery for brain hemorrhages.
This trial tests a rapid procedure to remove a blood clot in the brain after a specific type of stroke. It might help people with a moderate-sized bleed in the front part of the brain if treatment can start within 24 hours.
Hear when a new Intracerebral Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.